# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Centre for Clinical Practice – Surveillance Programme**

### **Recommendation for Guidance Executive**

### Clinical guideline

CG134: Anaphylaxis: assessment to confirm an anaphylactic episode and the decision to refer after emergency treatment for a suspected anaphylactic episode

#### **Publication date**

December 2011

### Surveillance decision for GE

July 2014

### Key findings

			Potential impact on guidance	
			Yes	Νο
Evidence from Evidence Update				~
Anti-discrimination and equalities considerations				$\checkmark$
No update	Rapid update	Standard update	Transfer to static list	Change review cycle
$\checkmark$				

### Surveillance proposal

Further to the publication of the Evidence Update on CG134: Anaphylaxis where no impacts were identified, GE is asked to consider the proposal to not update the guideline at this time.

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Centre for Clinical Practice – Surveillance Programme**

Surveillance review of CG134: Anaphylaxis: assessment to confirm an anaphylactic episode and the decision to refer after emergency treatment for a suspected anaphylactic episode

### **Recommendation for Guidance Executive**

### Background information

Guideline issue date: 2011 2 year review: 2013 NCC: Internal Clinical Guidelines

### Current two year surveillance review

- 1. The <u>Evidence Update</u> on CG134: Anaphylaxis was used as the primary source of evidence for this surveillance decision (search dates: 23 August 2010 to 19 October 2012). A summary of the evidence is provided in the Evidence Update.
- 2. The Evidence Update indicates that there is currently insufficient new evidence to invalidate the existing guideline recommendations. Therefore the Surveillance Programme recommends no update at this time.

2 of 3

## **On-going Research**

3. Not considered at 2 year review point.

### Anti-discrimination and equalities considerations

4. None identified through the Evidence Update.

### Implications for other NICE programmes

5. None identified through the Evidence Update.

### Surveillance recommendation

6. GE is asked to consider the proposal to not update the guideline at this time. GE are asked to note that as a 2 year surveillance decision this 'no to update' proposal will not be consulted on.

Mark Baker – Centre Director Sarah Willett – Associate Director Emma McFarlane – Technical Adviser

Centre for Clinical Practice